Keywords Diabetes Mellitus, Retinopathy, Neuropathy, Nephropathy, Cardiovascular Disease Share and Cite: Mohammed, S. , ...

Black children face rising type 2 diabetes risk. Learn to spot early warning signs, understand complications, and discover ...

Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD -- Asia-Pacific Partner’s New Drug ...

In patients with diabetes, semaglutide use was associated with an increased risk for nonarteritic anterior ischemic optic ...

Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) ...

The investigators conducted a prospective interventional study to determine the therapeutic anatomic and functional effects ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Kodiak ...

Also known as type 1.5 diabetes, here’s what to know about the onset, symptoms, diagnosis, and treatment options for latent ...

A new research paper was published in Aging (Aging-US) on January 31, 2025, in Volume 17, Issue 2, titled "Cysteinyl leukotriene receptor 1 modulates retinal immune cells, vascularity and proteolytic ...

ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.

LAS VEGAS, NV / ACCESS Newswire / March 25, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology ...

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...